Qingmu is an innovation driven pharmaceutical company
We have been operating for more than 10 years,the company specializes in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
About Us
Experience & trust built for 10+ years
Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).
Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
R & D
R & D Platform
Based on R&D concept “Green Chemistry “, Qingmu has gradually established key technical platforms such as asymmetric synthesis, transition metal catalysis (Cu, Fe, etc.), microchannel production, enzyme catalysis and drug crystallization process.
Manufacturing
Manufacturing System
Policy: People-oriented, health and safety, energy conservation and environmental protection, pollution prevention, full participation, sustainable development
Our News
News Center
Synthesis Methods of Lenvatinib Mesylate API
Sustainability in mRNA Raw Materials: Eco-Friendly Options and Practices
Ixazomib Citrate API: A Guide to Selecting the Right Ixazomib Manufacturer
Sourcing Strategies for High-Quality Gadobutrol API
Upadacitinib API in Ulcerative Colitis Treatment
Quality Control in Parecoxib Sodium API Production: Best Practices and Standards
Ixazomib Citrate API: A Weapon for Multiple Myeloma Treatment
